Seasonal COVID-19 vaccination delivered substantial clinical and economic benefits during the endemic phase of the virus, according to a major real-world study from Germany. Researchers analyzing health insurance data from over 3 million people found that vaccinated individuals had dramatically lower rates of long COVID, respiratory infections, and COVID-related hospitalizations compared to unvaccinated peers .

What Did the German Study Actually Find?

The ROUTINE-COV19 Study tracked 146,132 matched pairs of vaccinated and unvaccinated adults across two German states from September 2023 through March 2024. The vaccinated group showed a 57% reduction in long COVID cases, meaning the risk dropped to less than half of what unvaccinated individuals experienced. Beyond long COVID, vaccinated participants had a 9% lower rate of other respiratory infections and a striking 59% reduction in COVID-related hospitalizations .

Perhaps most notably, all-cause mortality was 25% lower among vaccinated individuals, suggesting the vaccine's protective effects extended beyond COVID-19 itself. The study used propensity score matching, a statistical method that pairs vaccinated and unvaccinated people with similar health profiles, making the comparison more reliable than simply comparing the two groups directly .

How Much Money Did Vaccination Actually Save?

The economic impact was substantial. Healthcare costs were significantly lower in the vaccinated cohort, particularly for hospital care. COVID-related hospitalizations alone saved approximately 1 million euros in direct medical expenses. Beyond hospital bills, the study calculated indirect costs from sick leave, finding that vaccination prevented an estimated 1.3 million euros in lost productivity .

These figures matter because they demonstrate that seasonal COVID-19 vaccination isn't just a personal health decision; it has measurable benefits for healthcare systems and economies. When a vaccine prevents hospitalizations and reduces time away from work, those savings compound across millions of people.

Why Does This Matter Now That COVID Is "Endemic"?

In April 2023, Germany integrated COVID-19 vaccination into routine care, moving away from the emergency response phase. This shift raised an important question: does seasonal vaccination still make sense when the virus is circulating at lower, more predictable levels? The ROUTINE-COV19 Study provides the first large-scale evidence that the answer is yes .

The research shows that even in the endemic phase, when COVID-19 is no longer causing pandemic-level disruption, the virus continues to cause serious illness in unvaccinated populations. Long COVID, in particular, remains a significant concern; the condition can cause persistent fatigue, breathing difficulties, and cognitive problems that last for months after initial infection.

How to Assess Whether Seasonal COVID-19 Vaccination Fits Your Health Needs

• Age and Risk Factors: The study included adults aged 18 and older, but vaccination recommendations typically prioritize older adults and people with chronic health conditions. Check with your healthcare provider about whether seasonal vaccination is recommended for your age and medical history.
• Prior Infection History: The study matched vaccinated and unvaccinated individuals, but didn't separate outcomes by prior COVID-19 infection status. If you've had COVID-19 recently, discuss with your doctor whether an additional vaccine dose is necessary or advisable.
• Occupational Exposure: People who work in healthcare, education, or other high-contact settings may benefit more from seasonal vaccination than those with limited exposure risk. Consider your workplace environment when deciding.
• Long COVID Concerns: If you're particularly worried about long COVID's lingering effects, the 57% risk reduction shown in this study may be especially relevant to your decision-making.

The German study used adapted COVID-19 vaccines targeting the Omicron XBB.1.5 variant, which were approved by the European Medicines Agency. The specific vaccines studied were Comirnaty and Spikevax, though the findings likely apply to other updated formulations as well .

What Do These Findings Mean for Public Health Policy?

The research supports continued implementation of national immunization recommendations during the endemic phase of SARS-CoV-2 circulation. Germany's approach of integrating COVID-19 vaccination into routine care, similar to annual flu shots, appears justified by the clinical and economic evidence. Other countries in Europe and beyond are watching these results as they develop their own long-term COVID-19 vaccination strategies .

The study's strength lies in its real-world design. Rather than relying on controlled clinical trials, researchers analyzed actual health insurance claims from millions of people, capturing what happens when vaccination is offered in routine medical practice. This approach reveals how well vaccines work outside of ideal research conditions, when people have varying levels of health literacy, access to care, and adherence to recommendations.

One important limitation: the study only followed participants for four months after vaccination. Longer-term data would help clarify whether the protective effects persist throughout an entire year or whether booster doses might be needed at different intervals. The research also focused on German populations, so findings may vary in other countries with different demographics or circulating virus variants.

As COVID-19 transitions from pandemic emergency to endemic disease, this evidence suggests that seasonal vaccination remains a valuable tool for reducing serious illness, long-term complications, and healthcare costs. The decision to vaccinate should be made in consultation with a healthcare provider who understands your individual risk factors and medical history.